NCT04174079View on ClinicalTrials.gov

Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma

NARecruitingINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions
Thoracic Esophageal Squamous Cell Carcinoma
Interventions
DRUG

chemotherapy

patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen Uniersity Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER